NCT06697301ClinicalTrials.gov ↗
The study is for patients with advanced melanoma who are eligible for standard therapy with Pembrolizumab.
A Phase 3 Study to Evaluate Petosemtamab Compared With Investigator's Choice Monotherapy in Previously Treated Head and Neck Squamous Cell Carcinoma Patients (LiGeR-HN2)
NCT06496178Original on ClinicalTrials.gov ↗
⚠️
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
This trial is no longer recruiting — here are similar active trials
Matched by cancer type/biomarker, currently recruiting.
NCT06216301ClinicalTrials.gov ↗
This study, known as LUNAR-2, aims to investigate the effectiveness and safety of using TTFields, delivered by the NovoTTF-200T device, concomitantly administered with pembrolizumab and platinum-based chemotherapy for patients with advanced non-small cell lung cancer that has spread to other parts of the body. The primary goals of the study are to assess overall survival and progression-free survival. Secondary objectives include analyzing outcomes based on the specific histology (subtype) of the lung cancer.
NCT07700979ClinicalTrials.gov ↗
The goal of this randomized, double-blind, multi-regional phase 3 study of cadonilimab combined with chemotherapy versus chemotherapy in combination with or without nivolumab for the first-line treatment of participants with HER2-negative, previously untreated, unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma trial is to compare OS between cadonilimab combined with chemotherapy and chemotherapy in combination with or without nivolumab in the ITT population.
NCT07623174ClinicalTrials.gov ↗
Metastatic colorectal cancer or mCRC is a cancer that starts in the parts of the large intestine (the colon or rectum) and has already spread to other parts of the body. This cancer can be hard to treat because it can behave differently from one person to another. Over time, treatments may stop working, and side effects can build up. In later treatment stages, there are only a few standard medicine options available. Because of this, studies often look at both how long people live and how treatment affects quality of life. The main aim of this study is to see how long adults in Poland with mCRC live without their cancer getting worse (progression-free survival or PFS) when they receive fruquintinib after at least two previous treatments. Fruquintinib (TAK 113) is a medicine taken by mouth that is designed to slow tumor growth. Other aim is to find out how long adults in Poland with mCRC live while being treated with fruquintinib (overall survival or OS). The study also wants to record how fruquintinib is used in routine care in adults with mCRC in Poland (for example when treatment starts, changes in doses, and how long treatment continues). Another aim is to learn about people with mCRC, such as their medical history and past treatment as well as their quality of life while they are in the study. The study will look at data already existing in the participants' medical charts.
About the trial
This is a phase 3 open-label, randomized, controlled, multicenter study to compare petosemtamab vs investigator's choice monotherapy in HNSCC patients for the second- and third-line treatment of incurable metastatic/recurrent disease.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Wiek co najmniej 18 lat
- •Potwierdzony rak głowy i szyi (płaskonabłonkowy) z przerzutami lub zaawansowaną chorobą, której nie można leczyć z nadzieją na całkowite wyleczenie
- •Choroba obejmuje obszary: gardła, jamy ustnej, gardła dolnego lub krtani
- •Choroba pogorszyła się mimo wcześniejszego leczenia immunoterapią i chemioterapią
- •Możliwość zmierzenia rozmiarów guza na zdjęciach (tomografia, rezonans)
- •Ogólny stan zdrowia pozwalający na leczenie (nie więcej niż mała aktywność fizyczna)
- •Oczekiwana długość życia co najmniej 12 tygodni
- •Wystarczająca funkcja głównych narządów (wątroba, nerki, serce)
✗ Disqualifies
- •Przerzuty do mózgu, które nie są leczone lub powodują objawy
- •Przerzuty do opon mózgowo-rdzeniowych
- •Chemioterapia lub inne leczenie przeciwnowotworowe w ostatnich 4 tygodniach
- •Poważne zaburzenia serca lub zawał w ostatnich 6 miesiącach
- •Ciężkie objawy uboczne z poprzednich leczeń
- •Historia alergii na składniki badanego leku
- •Inne nowotwory w historii (z pewnymi wyjątkami)
- •Problemy z oddychaniem w spoczynku lub wymóg stałego tlenu
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- September 25, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (194)
Site 160
Mobile, United States
Site 102
Prescott, United States
Site 125
Scottsdale, United States
Site 82
Duarte, United States
Site 25
La Jolla, United States
Site 173
Orange, United States
Site 28
Palo Alto, United States
Site 127
Sacramento, United States
Site 46
San Francisco, United States
Site 130
Lone Tree, United States
Site 104
Washington D.C., United States
Site 12
Fort Myers, United States
Site 123
Jacksonville, United States
Site 9
Orlando, United States
Site 138
Tampa, United States
Site 187
Atlanta, United States
Site 152
Chicago, United States
Site 213
Chicago, United States
Site 68
Chicago, United States
Site 31
Indianapolis, United States
Site 8
Louisville, United States
Site 40
Baton Rouge, United States
Site 100
New Orleans, United States
Site 153
Columbia, United States
Site 77
Boston, United States
Site 103
Ann Arbor, United States
Site 5
Detroit, United States
Site 49
Maple Grove, United States
Site 124
Rochester, United States
Site 18
St Louis, United States
Site 86
Hackensack, United States
Site 15
Albuquerque, United States
Site 24
New York, United States
Site 214
The Bronx, United States
Site 98
Chapel Hill, United States
Site 122
Durham, United States
Site 23
Cincinnati, United States
Site 218
Cleveland, United States
Site 87
Cleveland, United States
Site 32
Columbus, United States
Site 26
Portland, United States
Site 151
Bensalem, United States
Site 158
Philadelphia, United States
Site 50
Charleston, United States
Site 60
Chattanooga, United States
Site 54
Memphis, United States
Site 59
Nashville, United States
Site 67
Nashville, United States
Site 55
Denison, United States
Site 34
El Paso, United States
Site 51
Houston, United States
Site 7
Houston, United States
Site 94
Pearland, United States
Site 4
Salt Lake City, United States
Site 10
Blacksburg, United States
Site 22
Charlottesville, United States
Site 156
Winchester, United States
Site 163
Seattle, United States
Site 6
Spokane, United States
Site 216
Madison, United States
Site 58
Caba, Argentina
Site 45
Córdoba, Argentina
Site 110
Rosario, Argentina
Site 57
Viedma, Argentina
Site 3
Darlinghurst, Australia
Site 170
Herston, Australia
Site 38
Melbourne, Australia
Site 30
Nedlands, Australia
Site 11
Saint Leonards, Australia
Site 73
Sydney, Australia
Site 56
Brussels, Belgium
Site 92
Ghent, Belgium
Site 72
Leuven, Belgium
Site 108
Liège, Belgium
Site 69
Namur, Belgium
Site 154
Brasília, Brazil
Site 145
Porto Alegre, Brazil
Site 150
Porto Alegre, Brazil
Site 146
Recife, Brazil
Site 148
Rio de Janeiro, Brazil
Site 147
São Paulo, Brazil
Site 144
São Paulo, Brazil
Site 172
Montreal, Canada
Site 196
Toronto, Canada
Site 16
Providencia, Chile
Site 20
Recoleta, Chile
Site 27
Santiago, Chile
Site 21
Santiago, Chile
Site 201
Olomouc, Czechia
Site 105
Bordeaux, France
Site 211
Brest, France
Site 162
Le Mans, France
Site 149
Lille, France
Site 118
Lyon, France
Site 115
Marseille, France
Site 106
Montpellier, France
Site 169
Nice, France
Site 114
Paris, France
Site 167
Paris, France
Site 136
Poitiers, France
Site 141
Rennes, France
Site 107
Rouen, France
Site 119
Toulouse, France
Site 142
Vandœuvre-lès-Nancy, France
Site 113
Villejuif, France
Site 121
Berlin, Germany
Site 210
Dresden, Germany
Site 165
Essen, Germany
Site 84
Giessen, Germany
Site 62
Greifswald, Germany
Site 112
Hanover, Germany
Site 116
Leipzig, Germany
Site 168
München, Germany
Site 99
Würzburg, Germany
Site 91
Athens, Greece
Site 120
Heraklion, Greece
Site 126
Rio, Greece
Site 83
Thessaloniki, Greece
Site 204
Nyíregyháza, Hungary
Site 195
Pécs, Hungary
Site 198
Szeged, Hungary
Site 19
Haifa, Israel
Site 1
Jerusalem, Israel
Site 14
Ramat Gan, Israel
Site 2
Tel Aviv, Israel
Site 93
Brescia, Italy
Site 111
Cuneo, Italy
Site 128
Milan, Italy
Site 81
Milan, Italy
Site 209
Naples, Italy
Site 89
Naples, Italy
Site 203
Roma, Italy
Site 85
Rozzano, Italy
Site 132
Chūōku, Japan
Site 192
Fukuoka, Japan
Site 131
Kashiwa, Japan
Site 135
Miki, Japan
Site 139
Nagoya, Japan
Site 186
Natori, Japan
Site 133
Ōsaka-sayama, Japan
Site 134
Sendai, Japan
Site 180
Kaunas, Lithuania
Site 181
Vilnius, Lithuania
Site 76
Amsterdam, Netherlands
Site 61
Nijmegen, Netherlands
Site 66
Utrecht, Netherlands
Site 190
Bydgoszcz, Poland
Site 143
Gdansk, Poland
Site 97
Gliwice, Poland
Site 177
Krakow, Poland
Site 200
Lodz, Poland
Site 117
Poznan, Poland
Site 179
Warsaw, Poland
Site 182
Coimbra, Portugal
Site 183
Lisbon, Portugal
Site 185
Porto, Portugal
Site 161
Busan, South Korea
Site 13
Goyang-si, South Korea
Site 29
Hwasun, South Korea
Site 137
Seoul, South Korea
Site 36
Seoul, South Korea
Site 47
Seoul, South Korea
Site 33
Soeul, South Korea
Site 164
Suwon, South Korea
Site 78
Barcelona, Spain
Site 109
Madrid, Spain
Site 75
Madrid, Spain
Site 71
Madrid, Spain
Site 166
Madrid, Spain
Site 63
Pamplona, Spain
Site 64
Pamplona, Spain
Site 74
Valencia, Spain
Site 184
Bellinzona, Switzerland
Site 189
Geneva, Switzerland
Site 194
Lausanne, Switzerland
Site 178
Sankt Gallen, Switzerland
Site 17
Kaohsiung City, Taiwan
Site 95
Kaohsiung City, Taiwan
Site 53
Taichung, Taiwan
Site 176
Tainan, Taiwan
Site 35
Taipei, Taiwan
Site 52
Taoyuan City, Taiwan
Site 65
Cambridge, United Kingdom
Site 174
Cardiff, United Kingdom
Site 171
Glasgow, United Kingdom
Site 44
Liverpool, United Kingdom
Site 157
London, United Kingdom
Site 140
London, United Kingdom
Site 90
London, United Kingdom
Site 42
London, United Kingdom
Site 48
Manchester, United Kingdom
Site 70
Middlesex, United Kingdom
Site 191
Newcastle upon Tyne, United Kingdom
Site 43
Sutton, United Kingdom
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 7/17/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.